What is the size of the TCR-Based Antibody market in 2023?

The TCR-Based Antibody market size is USD 3600.4 million in 2023.

What is the projected CAGR at which the TCR-Based Antibody market is expected to grow at?

The TCR-Based Antibody market is expected to grow at a CAGR of 15.2% (2024-2033).

List the segments encompassed in this report on the TCR-Based Antibody market?

Market.US has segmented the TCR-Based Antibody market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Target Antigen the market has been segmented into NY-ESO-1, p53, WT-1, Ebv. By Indication the market has been segmented into Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Other Indications. By End-Users the market has been segmented into Hospitals, Specialized Clinics, Pharma & Biotech Research Laboratories, Gene Therapy Centers.

List the key industry players of the TCR-Based Antibody market?

Lion TCR, GlaxoSmithKline, Adaptimmune Therapeutics PLC, Celgene Corporation, Immunocore, Kuur Therapeutics Limited, Lion TCR Pte. Ltd., Kite Pharma, Takara Bio Inc., Ziopharm Oncology Inc., Merck & Co. Inc.

Which region is more appealing for vendors employed in the TCR-Based Antibody market?

North America is expected to account for the highest revenue share of 36% and boasting an impressive market value of USD 1296.1 million. Therefore, the TCR-Based Antibody industry in North America is expected to garner significant business opportunities over the forecast period.

Name the key areas of business for TCR-Based Antibody?

The US, Canada, India, China, UK, Japan, & Germany are key areas of operation for the TCR-Based Antibody Market.

Global TCR-Based Antibody Market Analysis By Target Antigen (NY-ESO-1, p53, WT-1, Ebv), By Indication (Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Other Indications), By End-Users (Hospitals, Specialized Clinics, Pharma & Biotech Research Laboratories, Gene Therapy Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Feb 2024
Report ID: 84335
Number of Pages: 227
Format:

- Lion TCR
- GlaxoSmithKline
- Adaptimmune Therapeutics PLC
- Celgene Corporation
- Immunocore
- Kuur Therapeutics Limited
- Lion TCR Pte. Ltd.
- Kite Pharma
- Takara Bio Inc.
- Ziopharm Oncology Inc.
- Merck & Co. Inc.
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 84335
Published Date Feb 2024
Rating
- ★★★★★
  
  ★★★★★
- (95)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)